Respiri Limited has provided Appendix 4E for the 12 months ending on 30 June 2024.

Respiri Limited (ASX: RSH) reported a strong performance in Appendix 4E for the 12 months ending 30 June 2024. The company achieved a remarkable revenue of AU$1 million for the June 2024 financial year, which includes an operating income of AU$0.5 million, marking an impressive 511% increase from the previous year's operating revenue of AU$0.1 million. The last quarter of the financial year was outstanding, contributing a record AU$190,000 in operating income.

This financial year saw significant growth in patient numbers on remote patient monitoring and other programs and an increase in the number of healthcare organisation clients from 15 to 26. The company has active programs to ensure expedited patient onboarding in the current quarter and beyond. With a modest 33% conversion rate and a planned complete onboarding kick-off in September, Respiri aims to increase patient numbers by an additional 3,000 from these clients. Moreover, the company anticipates securing more RPM contracts from new clients, including significant accounts with Payor/health insurers, IPAs/ACOs, and other healthcare organisations with these patient populations, in addition to the existing clients.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com